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Methods: 
 
The impact of anemia on mortality was studied, and its incre-
mental predictive value was evaluated. Demographic, clinical, and biologic
characteristics at admission, as well as treatments and mortality, were recorded
for 1,410 consecutive patients with acute coronary syndromes. The incre-
mental value of adding anemia information to risk score evaluation was deter-
mined using changes in the appropriateness of Cox models when anemia was
added.
 
Results:
 
 Anemia was detected in 381 patients (27%). They were older, had
more co-morbidities, had higher Global Registry of Acute Coronary Events
(GRACE) risk scores, received fewer guideline-recommended treatments, and,
as a result, had 4-fold higher mortality. When included in a prediction model
based on the GRACE risk score, anemia remained an independent predictor of
mortality. The addition of anemia improved both the discriminatory capacity
and calibration of the models. According to the GRACE risk score, the popu-
lation was divided into 4 groups of different risk levels of <1%, 1% to <5%,
5% to <10%, and > or =10%. The addition of anemia to the model made it
possible to reclassify 9%, 43%, 47%, and 23% of patients into the different
risk categories, respectively.
 
Conclusion:
 
 Our data confirmed that anemia was an independent predic-
tive factor of mortality and had incremental predictive value to the GRACE
score system for early clinical outcomes.
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Background:
 
 Determination of appropriate dosing of antithrombotic drugs
is difficult, and clinical studies to define appropriate monitoring techniques are
needed.
 
Objective:
 
 We compared the endogenous thrombin potential (ETP) in
patients planning to undergo percutaneous coronary intervention (PCI) being
pre-treated with a combination of two or three antiplatelet agents and with
fondaparinux or unfractionated heparin (UFH). Pre-treatment was dependent
upon clinical presentation. Calibrated Automated Thrombography was per-
formed in voluntary blood donors and in patients submitted to PCI. Thrombin
generation was studied in platelet poor plasma by a fluorimetric technique.
 
Patients/Methods:
 
 A total of 152 patients were included. Group 1 patients
were pre-treated with aspirin alone, group 2 were pre-treated with aspirin and
clopidogrel, group 3 were treated with a combination of aspirin, clopidogrel,
and 2.5 mg fondaparinux, group 4 were treated with aspirin, clopidogrel, 2.5
mg fondaparinux, and tirofiban, and group 5 received a bolus of 50 IU/kg
UFH plus antiplatelet agents.
 
Results:
 
 Compared with voluntary blood donors, there was a significant
decrease in ETP in group 2. The addition of fondaparinux (group 3) induced
a 24% decrease in ETP; a further 25% decrease in ETP was observed between
groups 3 and 4. No thrombin generation was observed after UFH treatment.
 
Conclusion:
 
 Assessment of thrombin generation is potentially very useful
in the setting of PCI, where a combination of antiplatelet agents and an anti-
coagulant is mandatory.
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Background:
 
 Cardiac magnetic resonance imaging (MRI) is the gold stan-
dard to quantify the infarct size and the extend of microvascular obstruction in
ST-elevation myocardial infarction (STEMI). ST-segment resolution (STR)
after primary percutaneous intervention (PCI) is currently used to assess the
reperfusion quality in the acute phase myocardial infarction. The relation
between STR and microvascular obstruction evaluated by MRI is unknown.
The aim of this study was to determine the relationship between the ST-seg-
ment resolution, the infarct size and the extend of microvascular obstruction.
 
Methods:
 
 41 patients undergoing primary PCI for STEMI within 6 hours
of symptom onset were prospectively included. ST-segment resolution was
evaluated one hour after reperfusion. MRI was performed in all patients. Com-
plete STR was defined as a STR>70%.
 
Results:
 
 Mean age of the patients was 54 Â± 12 yo, 85 waer males. The
percent of infarct size was 18,6 Â±16% of the left ventricular volume.
Microvascular obstruction was present in 68% of patients. Mean STR was 59
Â± 39% and 14 patients (34%) presented complete STR. A large infarct size
(> 75
 
th
 
 percentile) was associated with anterior localisation and left descending
artery obstruction. STR significantly correlated with infarct size measured by
MRI (r=-0,38 p=0,026). Incomplete STR (<70%) predicted large infarct size
with a sensitivity of 78%, a specificity of 42% and high degree of microvas-
cular obstruction with sensitivity of 80% and specificity of 45%.
 
Conclusion:
 
 STR one hour after primary PCI is associated with the level
of infarct size and microvascular obstruction in STEMI patients. Incomplete
STR after PCI is a strong prognostic marker of large infarct size and high
degree of micro vascular obstruction.
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Background:
 
 The presence of preinfarction angina (PIA) has been shown
to confer cardioprotection after ST segment elevation myocardial infarction
(MI). However, the impact of PIA in non ST segment elevation (NSTEMI)
remains to be determined.
 
Patients and Methods:
 
 From the obseRvatoire des Infarctus de Côte d’Or
(RICO) survey, 1541 consecutive patients admitted in intensive care unit with
a first NSTEMI were included in the study. Patients who experienced chest
pain <7 days before the episode leading to admission were defined as having
PIA. Patients presenting with PIA were compared with patients without PIA.
Prehospital resuscitated cardiac arrest (RCA), incidence of in-hospital ventri-
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cular arrhythmias (VA), heart failure (Killip class>1) and 30-day mortality
were collected.
 
Results:
 
 Among the 1541 patients included in the study, 693 patients
presented PIA. Baseline clinical characteristics were similar for the 2
groups. There was no significant difference for the GRACE risk score
(p=0.942). However, PIA was associated with a lower creatine kinase
peak, as a reflect of infarct size (231(109-520) vs. 322(148-844) IU/L,
p<0.001) and a lower rate of patients with a troponin peak >100 ULN
(31% vs. 39%, p<0.001) when compared with the group without PIA.
Patients with PIA were admitted with markedly less pre-hospital RCA
(0.6% vs. 3.4%, p<0.001) and developed fewer VA (1.6% vs. 4.0%,
p=0.008) and heart failure (18.2% vs. 22.6%, p=0.037) during the hospital
stay. There was a trend toward a decrease in 30-day death in patients with
PIA (4.3% vs 6.1%, p=0.146).
 
Conclusion:
 
 From this large contemporary observational study, PIA is
observed in almost 50% of patients admitted for a first NSTEMI. In such
patients, PIA is associated with less pre-hospital RCA, and decreased in-hos-
pital VA and heart failure. These findings suggest that identifying lack of PIA
in patients admitted for a NSTEMI could help for early risk stratification, in
particular for ventricular arrhythmias.
 
014
 
Risk score to predict serious bleeding in stable outpatients with athe-
rothrombosis
 
Gregory Ducrocq (1), Joshua Wallace (2), Gabriel Baron (3), Philippe
Ravaud (4), Mark Alberts (5), Peter Wilson (6), Magnus Ohman (7), Danielle
Brennan (8), Ralph D’Agostino (9), Deepak Bhatt (10), Ph Gabriel Steg
(1)
 
(1) APHP, Hôpital Bichat-Claude Bernard, INSERM, U698, Université
Paris 7, Paris, France – (2) INSERM, U738, Paris, France; Université
Paris 7 Denis Diderot, UFR de Médecine, Paris, France – (3) AP-HP,
Hôpital Bichat, Département d’Epidémiologie, Biostatistique et Recherche
Clinique, Paris, France – (4) AP-HP, Hôpital Bichat, Département d’Epi-
démiologie, Biostatistique et Recherche Clinique, Paris, France – (5) Nor-
thwestern University Feinberg School of Medicine, Chicago, Il, Etats-Unis
– (6) Emory School of Medicine, Atlanta, Ga, Etats-Unis – (7) Duke Uni-
versity, Durham, Nc, Etats-Unis – (8) Cleveland Clinic, Cleveland, Oh,
Etats-Unis – (9) Boston University, Boston, Ma, Etats-Unis – (10) VA
Boston Healthcare System and Brigham and Women’s Hospital, Boston,
Ma, Etats-Unis
 
Context:
 
 Assessment of bleeding risk is often crucial for making decisions
regarding chronic use of antithrombotics.
 
Objective:
 
 To develop a risk score to quantify bleeding risk in outpa-
tients. Design, Setting, and Participants We studied patients enrolled in the
Reduction of Atherothrombosis for Continued Health (REACH) Registry,
a cohort of 68 236 patients with or at risk of atherothrombosis. The out-
come of interest was serious bleeding (non-fatal hemorrhagic stroke or
bleeding requiring hospitalization and transfusion) over 2 years. Risk fac-
tors for bleeding were assessed using modified regression analysis. Mul-
tiple potential scoring systems based on the least complex models were
constructed. Competing scores were compared on their discriminative abi-
lity via logistic regression. The score was validated externally using the
CHARISMA population.
 
Results:
 
 From a final cohort of 56 616 patients, 804 (1.42%) experienced
serious bleeding between baseline and 2 years. A nine-item bleeding risk
score, ranging from 0 to 23 points, was constructed including age, peripheral
arterial disease, congestive heart failure, diabetes, hypertension, smoking, anti-
platelets, oral anticoagulants, and hypercholesterolemia. Observed incidence
of bleeding at 2 years was: 0.46% in patients with a score 
 
≤
 
6; 0.95% for scores
7-8; 1.25% for scores 9-10; and 2.76% for scores 
 
≥
 
11. The score’s discrimi-
native performance was consistent in CHARISMA and REACH (c-statistics
0.63 and 0.68, respectively); calibration in the CHARISMA population was
very good (modified Hosmer-Lemeshow 
 
χ
 
2
 
=4.74; 
 
P
 
=.69).
 
Conclusions:
 
 Bleeding risk increases dramatically with a score >10. This
score can assist clinicians in predicting the risk of serious bleeding and making
decisions on antithrombotic therapy in outpatients with atherothrombosis.
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Aim:
 
 The CHADS
 
2
 
 score is a reliable, easy-to-use, and popular bedside
score to assess the risk of stroke in patients with atrial fibrillation (AF). The
items of the score are all key determinants of prognosis in vascular patients.
We compare CHADS
 
2
 
 to established scores (the Framingham score and the
European SCORE) for their ability to predict adverse cardiovascular outcome
in atherothrombotic patients without AF.
 
Methods: 
 
Individual risk scores were calculated in 18,888 stable athe-
rothrombotic patients without AF included in the European REACH registry in
18 European countries between 2003 and 2004. Each scheme was divided into
low, intermediate and high predicted risk categories and applied to the cohort.
MACCE (CV Death, MI or Stroke) were recorded at 2 years follow-up.
 
Results:
 
 Two hundred six deaths and 987 MACCE occurred during 37776
patients-years follow up. According to CHADS
 
2
 
 score, 38.2% (7234 patients with
CHADS
 
2
 
=0-1) had low, 48.2% (9101 patients with CHADS
 
2
 
=2-3) had interme-
diate and 13.5% had high predicted CV risk (2553 patients with CHADS
 
2
 
=4-6)
(figure A). The proportion of individual assigned to individual risk categories
varied widely across schemes (low risk ranged from 26.6 % to 88.6%, high risk
from 1.5% to 25.0%). Although the risk scores had only poor discriminating abi-
lity, CHADS
 
2
 
 had the higher c-statistics of 0.613 (figure B). In multivariable
logistic regression, the CHADS
 
2
 
 score (high vs low risk) remains an independent
predictor of MACCE even after adjustement to Framingham score (OR 2.78 [95%
CI 2.3 to 3.3] ) or european SCORE (OR 2.94 [95% CI 2.45 to 3.5] ).
 
Conclusions:
 
 The CHADS
 
2
 
, a reliable, easy-to-use, bedside score, appears
to predict more accurately, adverse cardiovascular outcome in atherothrom-
botic patients without atrial fibrillation, than established scores. But current
risk scheme have limited ability and better scores are needed.
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Objective:
 
 Recent findings reported intriguing relationships between obe-
sity and natriuretic peptides. In patients with acute myocardial infarction (MI),
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